Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS)
(Delayed Data from NYSE)
$17.75 USD
+0.06 (0.34%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $17.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SBS 17.75 +0.06(0.34%)
Will SBS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SBS
Here's Why Sabesp (SBS) is Poised for a Turnaround After Losing -11.66% in 4 Weeks
SBS or GWRS: Which Is the Better Value Stock Right Now?
SBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) Stock?
Here's What Could Help Sabesp (SBS) Maintain Its Recent Price Strength
Are Utilities Stocks Lagging E.ON (EONGY) This Year?
Other News for SBS
SBS Stock Earnings: Companhia De Saneamento Beats EPS, Beats Revenue for Q2 2024
Hauck & Aufhaeuser Sticks to Its Hold Rating for STRATEC Biomedical (0RAR)
Kepler Capital Reaffirms Their Hold Rating on STRATEC Biomedical (0RAR)
Berenberg Bank Remains a Hold on STRATEC Biomedical (0RAR)
Warburg Research Sticks to Their Hold Rating for STRATEC Biomedical (0RAR)